Warsaw, Poland – 14 November 2022 – Molecure S.A. (“Molecure”: WSE: MOC) a clinical stage biotechnology company that uses its world leading medicinal chemistry capabilities to discover first-in-class small molecule drug candidates that directly modulate unexplored
Read moreMolecure Third Quarter 2022 Pipeline Highlights and Financial Results Proprietary pipeline progressing in-line with our strategic objectives for 2022-2025 Lead proprietary candidate, OATD-01 a novel chitinase inhibitor in sarcoidosis expected to advance into a Phase II
Read moreOur new name “Molecure” reflects expansion of scope of small molecule targets from novel proteins to mRNA in discovery & development of breakthrough therapies for multiple diseases Worldwide rights regained to novel, dual chitinase inhibitor OATD-01
Read moreUDA-POIG.01.04.00-14-374/13 - Opracowanie selektywnych inhibitorów kwaśnej chitynazy ssaków do leczenia astmy Celem ogólnym projektu jest opracowanie związku o działaniu przeciwastmatycznym, którego parametry pozwolą na wprowadzenie go do badań klinicznych, dzięki czemu wzmocni się konkurencyjność Wnioskodawcy oraz pozycja
Read moreOATD-02 is an oral, potent and selective first in class, dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer. Following CTA approval, Molecure plans to initiate a Phase I clinical trial in late 2022
Read moreFollows an ongoing strategic portfolio review by partner Galapagos Molecure to regain all rights, associated data, IP and inventory to OATD-01 Evaluating potential first indication and development plan for the asset in sarcoidosis Warsaw, Poland June
Read moreUDA-POIG.01.03.01-14-094/12 - Opracowanie kandydata na lek przeciwnowotworowy na bazie nowej grupy związków OAT-449 Celem ogólnym Projektu jest poprawa innowacyjności i w konsekwencji zwiększenie konkurencyjności polskich przedsiębiorstw a tym samym polskiej gospodarki dzięki realizacji badań w obszarze
Read moreMolecure is a clinical stage biotechnology company that uses its world leading medicinal chemistry and biology capabilities to discover and develop first-in-class small molecule drug candidates that directly modulate underexplored protein targets and the function of
Read moreMolecure, a clinical stage biotechnology company, discovers and develops breakthrough small molecule drugs that modulate unexplored protein targets and novel RNA to treat cancer, fibrotic and inflammatory diseases. Our exceptional in-house medicinal chemistry and biology capabilities,
Read more
